NEWS - FDA rules out bisphosphonate, thigh fracture link

[Guest guest]

FDA rules out bisphosphonate, thigh fracture link

Toni e

BOSTON

Wed Mar 10, 2010 6:47pm EST

BOSTON (Reuters) - U.S. regulators said on Wednesday they have found

no link between oral bisphosphonate osteoporosis medications such as

Merck & Co Inc's Fosamax and certain thigh bone fractures.

The U.S. Food and Drug Administration issued its statement following

the publication of case reports of atypical subtrochanteric femur

fractures - or fractures in the bone just below the hip joint - in

women with osteoporosis using oral bisphosphonates.

Bisphosphonates are a class of drug aimed at preventing bone fractures

and offsetting bone loss associated with menopause.

They include Fosamax, Roche Holding AG's Boniva, Novartis AG's Reclast

and Procter and Gamble Co's Actonel.

In June 2008, the FDA requested information from all bisphosphonate

drug makers related to these type of fractures. The agency said a

review of the data did not show an increased risk for women using the

medications.

The FDA said that, although its review of the data did not show a

clear connection between bisphosphonates and atypical subtrochanteric

femur fractures, the agency is working closely with outside experts to

gain more insight into the issue.

Bisphosphonates, which have been on the market for roughly a decade,

have raised safety concerns in the past, including heart risks.

But in 2008, the FDA said the drugs showed no overall risk of heart

problems. The agency's review followed reports of serious atrial

fibrillation, a type of abnormal heartbeat, in the New England Journal

of Medicine.

In January, a Manhattan federal judge refused to dismiss a lawsuit

alleging that Fosamax caused jaw damage to a woman during the nearly

eight years she took the pill.

Merck faces a slew of lawsuits involving almost 900 cases by patients

who say Fosamax caused osteonecrosis of the jaw, or death of jaw bone

tissue.

The FDA recommended patients keep taking their medication unless told

not to by their doctor. It also recommended that healthcare

professionals be aware of a " possible risk " of atypical

subtrochanteric femur fractures in patients taking oral

bisphosphonates.

http://www.reuters.com/article/idUSTRE6295LZ20100310

Not an MD